Home>Topics>Stocks>Nektar Therapeutics

Nektar Therapeutics NKTR

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. Nektar Therapeutics' ( NKTR ) CEO Howard Robin on Q2 2014 Results - Earnings Call Transcript


      Thu, 31 Jul 2014

      Nektar Therapeutics (NASDAQ: NKTR ) Q2 2014 Earnings Conference Call July 31, 2014 5:00 PM ET Executives ..... Operator Good day, ladies and gentlemen, and welcome to the Nektar Therapeutics Second Quarter 2014 Financial Results Conference Call. At

    2. Nektar: Reason Will Rarely Fail You


      Mon, 28 Jul 2014

      year for biotechnology investing! Even stocks that scream "sure bet" and "buy now" are getting reamed. Nektar (NASDAQ: NKTR ) is no exception. My biotech portfolio is all paper red and I'm embarrassed. I'm hoping for a big turnaround, but realistically

    3. Patient enrollment for Synergy OIC drug trial complete


      Thu, 17 Jul 2014

      bowel movements during Week 4 of the Treatment Period. Synergy intends to release top-line data from the trial in Q4. Related tickers: ( NKTR -5.2% ) ( AZN -2.1% ) ( CBST -0.8% ) ( SLXP -1.6% ) ( PGNX ) Post your comment!

    4. New CMO at Cara


      Tue, 24 Jun 2014

      company's lead compound, CR845 , in addition to its pipeline of pain therapies. Dr. Medve joins Cara from Nektar Therapeutics ( NKTR +0.7% ) where he was SVP and CMO in charge of clinical development strategy. Post your comment!

    5. Nektar receives $19.75M payment


      Wed, 18 Jun 2014

      technology to develop, manufacture and sell Fovista , Nektar Therapeutics ( NKTR ) receives a $19.75M payment from its partner ..... fee. This was the basis for paying $19.75M to NKTR . NKTR is entitled to as much as $9.5M in additional

    6. Regado Biosciences: The Revolixys Revolution Has Begun


      Tue, 17 Jun 2014

      By Scrying Biotech : I like biotechnology companies that are underpriced relative to their peers, but also to their prospects. And Regado Biosciences ( RGDO ) is shepherding a disruptive and potentially dominant cardiovascular therapy towards commercialization. Focused on developing acute care ...

    7. Nektar Therapeutics pain drug for knee arthritis fails study


      Thu, 26 Sep 2013

      (Reuters) - Nektar Therapeutics said its experimental drug to treat chronic pain in patients with arthritis of the knee failed to meet its main goal in a mid-stage clinical trial.

    8. OGICX Oppenheimer Global Opportunities C Fund Analysis, Report, Research, 5 Star Rating – Morningstar

      Fund Reports

      Wed, 2 Nov 2011

      one of the fund's struggling top positions-- Nektar Therapeutics NKTR --slid even further in the downdraft. Several ..... patches. Jennings has held on to top positions in Nektar Therapeutics and Advanced Micro Devices AMD through thick and

    9. New Morningstar Analyst Report - Flamel Technologies

      Stock Reports

      Tue, 29 Jun 2010

      surrounding Flamel's early stage pipeline.Flamel may be left empty-handed if competitors such as Alkermes ALKS, Nektar NKTR , and Biovail BVF develop technology superior to the company's Micropump and Medusa systems.Micropump is the only one of

    10. Dropping Coverage of Nektar


      Mon, 27 Jul 2009

      We are dropping coverage of Nektar Therapeutics NKTR to focus our resources elsewhere.

    « Prev123Next »
    Content Partners